Castrate resistant prostate cancer (CRPC) refers to prostate cancer that continues to progress even after hormone therapy. It is an advanced stage of prostate cancer with limited treatment options. Despite primary and secondary hormonal therapies, the cancer often becomes castrate-resistant. Drugs for CRPC aim to improve survival and delay disease progression. Development of novel and effective treatment options is one of the major opportunities boosting the market growth. Promising drugs in the pipeline are expected to enter the market over the forecast period.
The global Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Increasing Disease Prevalence: Prostate cancer has a high prevalence worldwide. According to estimates, there were 1.4 million new cases and 375,000 deaths from prostate cancer globally in 2020. The rising disease burden is expected to drive the demand for effective treatment options, thus propelling the castrate resistant prostate cancer market growth over the forecast period.
Promising Pipeline Candidates: Development of new molecules targeting resistance pathways is a major focus area for many pharmaceutical companies. Drugs such as apatorsen (HMI-217), oleclumab (anti-CD73 mAb), and opdivo (nivolumab) have shown promising results in clinical trials. Their approvals will increase treatment options and drive the market in coming years.
The global Castrate Resistant Prostate Cancer market can be segmented by drug type into chemotherapy, hormone therapy, immunotherapy, and targeted therapy. The chemotherapy segment currently dominates the market due to drugs like docetaxel being the first line of treatment for metastatic Castrate Resistant Prostate Cancer. The chemotherapy segment accounted for approximately 45% of the overall market share in 2024 due to higher sales of docetaxel and cabazitaxel.
Political: Government regulations around drug development and approval processes affect the market. Governments provide funding for cancer research which drives drug innovation.
Economic: Developed markets dominate spending on Castrate Resistant Prostate Cancer treatment due to higher healthcare budgets. However, emerging countries provide lucrative growth opportunities due to rising disposal incomes.
Social: Increased awareness about prostate cancer diagnosis and treatment has positively impacted early detection. Support groups help patients cope with the disease.
Technological: Advancements in targeted therapy, immunotherapy, and combination regimens have improved treatment outcomes. Ongoing R&D is evaluating newer drug candidates and diagnostic techniques.
The Global Castrate Resistant Prostate Cancer Market Size is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: The North American region accounted for over 35% of the global market share in 2024 due to presence of key market players like Johnson & Johnson and Amgen in the US. The Europe region is the second largest market supported by availability of advanced treatment options and favorable reimbursements in countries like Germany and France. Asia Pacific is poised to be the fastest growing market during the forecast period led by India and China on account of rising disposable incomes, expanding healthcare infrastructure as well as increasing public awareness about cancer.
Key players operating in the Castrate Resistant Prostate Cancer market are Bucher Vaslin, Pera Pellenc, Scharfenberger, Zambelli Enotech, ENOTOOLS, Criveller Group, Della Toffola, Gruppo Bertolaso, Fabbri, Mori Luigi & C. Companies are focused on developing novel therapy combinations to improve treatment efficacy and patient outcomes.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it